Short Interest in Guided Therapeutics Inc. (OTCMKTS:GTHP) Decreases By 92.7%

Guided Therapeutics Inc. (OTCMKTS:GTHP) was the target of a significant decline in short interest during the month of July. As of July 15th, there was short interest totaling 1,437 shares, a decline of 92.7% from the June 30th total of 19,653 shares. Based on an average daily volume of 29,293 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the shares of the company are sold short.

Guided Therapeutics Price Performance

Shares of Guided Therapeutics stock traded down $0.01 during trading hours on Friday, hitting $0.25. 5,100 shares of the company’s stock traded hands, compared to its average volume of 8,281. Guided Therapeutics has a 12-month low of $0.12 and a 12-month high of $0.54. The stock has a market capitalization of $24.43 million, a price-to-earnings ratio of -6.33 and a beta of 0.72. The company has a fifty day simple moving average of $0.24 and a 200-day simple moving average of $0.28.

Guided Therapeutics (OTCMKTS:GTHP) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.01) earnings per share for the quarter.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.

The company secured 510(k) clearance from the U.S.